N-Acetyl Selank Amidate
A terminally capped variant of Selank sold on the promise of a longer half-life. A systematic search of PubMed and Europe PMC returns zero publications on it — the phrases do not exist in the biomedical index at all. Where an acetylated sibling peptide has been tested, capping the N-terminus changed its biology rather than simply extending it.
This is Selank with chemical caps on both ends, meant to stop enzymes chewing it up so each dose lasts longer. The idea is sound chemistry. The problem is that nobody has ever published a study on this exact molecule — not one, anywhere. Everything claimed for it is borrowed from the parent peptide, and when researchers did cap a closely related peptide, it behaved differently rather than just lasting longer.
What is N-Acetyl Selank Amidate?
N-Acetyl Selank Amidate is Selank — the tuftsin-derived heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro — with its N-terminus acetylated and its C-terminus amidated. Both modifications are standard medicinal chemistry: capping the free amino and carboxyl groups blocks aminopeptidase and carboxypeptidase cleavage at each end, which in general extends a peptide's half-life. The important fact about this compound is what does not exist. A systematic search of PubMed across five phrase variants — 'N-acetyl selank', 'acetyl selank', 'selank amidate', 'NA-selank' and 'N-acetyl-selank-amidate' — returns zero results, with PubMed reporting that none of the phrases appears in its index at all. Europe PMC returns zero, including preprints. ClinicalTrials.gov has no record. There is no pharmacokinetic study, no efficacy study, no toxicology study, and no analytical characterisation of the molecule in the peer-reviewed literature. Every property attributed to it is inherited from the parent peptide by assumption. That assumption is not obviously safe, and there is now direct evidence against treating it as safe. The closest analogue that has actually been studied is acetylated Semax, from the same Russian peptide family. A 2016 study in the Journal of Inorganic Biochemistry found that N-terminal acetylation altered Semax's copper coordination chemistry, shifted its redox behaviour, and — the pointed finding — 'Semax acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line, thus demonstrating the crucial role played by the free NH2 terminus in the cell protection.' When someone did cap the N-terminus of a sibling peptide and look, the modification removed a biological property rather than simply preserving the molecule for longer. Note also a naming asymmetry worth knowing: the published Semax work covers N-acetylation only. The full acetyl-plus-amidate combination has no literature for Semax either.
What N-Acetyl Selank Amidate Is Investigated For
Every use case for this compound is borrowed, and the parent peptide's record is better than this page previously conveyed. Selank itself has a real if geographically narrow clinical literature: a 62-patient comparator-controlled trial against medazepam in generalised anxiety disorder and neurasthenia found comparable anxiolytic effect with additional antiasthenic and psychostimulant properties; a 70-patient randomised trial found that adding Selank to phenazepam reduced benzodiazepine side effects including attention and memory impairment, asthenia and sedation, both during treatment and after tranquilliser withdrawal; and a 60-patient comparison against phenazepam reported anxiolytic plus mild nootropic effects that persisted for a week after the last dose. There is also modern human mechanistic work — a placebo-controlled resting-state fMRI study in 52 healthy participants found Selank altered right amygdala to right temporal cortex connectivity within 20 minutes of injection. None of that was done with the acetylated amidated variant. The gap between 'Selank has human trial data' and 'this product has human trial data' is total. The specific marketing claim — that terminal capping produces a clinically superior version — has never been tested in any species. The one piece of relevant evidence runs the other way: acetylating the N-terminus of the sibling peptide Semax abolished a protective effect and changed its metal-binding chemistry. Route matters too, and in a way that undercuts the assumption that pharmacokinetic tinkering is biologically neutral: a comparative study in mice found intraperitoneal Selank raised GABA receptor binding in frontal cortex by about 38% with no NMDA change, while intranasal Selank raised NMDA-site binding by about 23% with no GABA effect. The same peptide produced different receptor profiles by route. A molecule modified to change its disposition should not be assumed to preserve its pharmacology.
History & Discovery
The parent peptide Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, in the Sector of Regulatory Peptides, as a stabilised analogue of tuftsin — a naturally occurring immunopeptide. The design is explicit in the primary literature: Selank 'has a structure of tuftsin, to which three natural L-amino-acids Pro-Gly-Pro are attached,' producing the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Clinical development in Russia through the 2000s produced the comparator-controlled trials against medazepam and phenazepam that remain the compound's evidence base, and Selank is registered as an anxiolytic in the Russian Federation, appearing among fourteen peptide drugs catalogued in a 2022 peer-reviewed survey of the Russian register. This page previously said 'Russia and CIS countries'; no source for wider CIS registration could be found, so the narrower claim is the one stated. N-Acetyl Selank Amidate has no comparable lineage, and in fact has no documented origin at all. It is not a product of the Institute of Molecular Genetics programme, it is not registered anywhere, and no publication describes its synthesis, characterisation or testing. It appears to be a research-chemical-market creation: a standard medicinal-chemistry modification applied to a peptide with existing consumer demand, marketed on a theoretical pharmacokinetic argument. The same pattern produced N-acetyl Semax amidate, and it is worth noting that the acetylated Semax that has been studied is the N-acetylated form only — the full acetyl-plus-amidate combination has no literature for either peptide. The United States regulatory position on the parent is more concrete than generic 'not approved' language conveys. 'Selank acetate (TP-7)' appears on the FDA's list of bulk drug substances nominated for use in compounding and then withdrawn from consideration, with the agency stating that compounded drugs containing it 'may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities' and that it 'lacks important information regarding any safety issues raised by selank acetate administered to humans.' Semax appears in the same section with near-identical language. There is therefore no legitimate compounding route for the parent, and none has ever been sought for the variant. Repeated PubMed audits through 2026 continue to return nothing for the modified molecule. What has changed since earlier versions of this page is the recognition that the parent's literature is considerably richer than three references suggested — the file now cites the controlled trials, the GABA-A binding work, the electrophysiology, the BDNF and cytokine studies, and the 2020 fMRI study, none of which it previously carried.
How It Works
Selank calms anxiety by nudging the brain's main inhibitory system, GABA, without sedating or causing dependence. This version has chemical caps on both ends of the molecule, meant to stop enzymes from breaking it down so quickly. The intended result is more of the peptide reaching the brain from each dose. Whether that actually happens, and whether the capped molecule still behaves the same way once it arrives, has never been measured.
The parent peptide's mechanism is better characterised than this page previously indicated. Radioligand binding work from the originating institute identifies Selank as a positive allosteric modulator of GABA binding that blocks the modulation produced by diazepam and olanzapine, with binding sites apparently distinct from but possibly overlapping the benzodiazepine site. Patch-clamp recordings provide independent confirmation at the circuit level: Selank at 1-8 µM increased both the amplitude and the discharge rate of spontaneous inhibitory postsynaptic currents in rat hippocampal CA1 pyramidal neurons. Gene-expression studies in rat tissue and in a human neuroblastoma line show effects on genes involved in GABAergic neurotransmission. A second, older mechanism concerns enkephalins. Selank inhibits enkephalin-degrading enzymes in human serum with an IC50 around 20 µM, and patients with generalised anxiety disorder were found to have shortened leu-enkephalin half-life correlated with symptom severity — a plausible route by which an enkephalinase inhibitor produces anxiolysis. Neurotrophic effects are documented too: Selank protected against ethanol-induced memory impairment while regulating BDNF content in hippocampus and prefrontal cortex. Immunomodulation is real but narrower than often claimed — IL-6 suppression was demonstrated in peripheral blood from depressed patients, and IL-1β, IL-6, TNF-α and TGF-β1 were normalised in socially stressed rats. Interferon-gamma does not appear in any published Selank measurement, and this page no longer claims it. The terminal modifications are where inference takes over entirely. Acetylating the N-terminus and amidating the C-terminus blocks aminopeptidase and carboxypeptidase attack, which is a well-established half-life extension strategy. What is not established is that the capped molecule retains the parent's receptor and signalling profile. Two lines of evidence argue for caution. First, the acetylated Semax work: N-terminal acetylation modified copper complex geometry from a CuN4 to a distorted CuN3O chromophore, shifted the redox potential, and eliminated protection against copper-induced toxicity in neuroblastoma cells, with the free amino terminus identified as crucial to that effect. Second, route alone changes Selank's receptor profile — intraperitoneal dosing raised frontal cortex GABA receptor binding roughly 38% without affecting NMDA sites, while intranasal dosing raised NMDA-site binding roughly 23% without affecting GABA. If the delivery route reshapes which receptors respond, a structural modification to the molecule itself should not be assumed neutral.
Evidence Snapshot
Human Clinical Evidence
None for the modified form — zero publications exist. For the parent Selank: a 62-patient comparator-controlled trial against medazepam in generalised anxiety disorder and neurasthenia, a 70-patient randomised trial of Selank added to phenazepam showing reduced benzodiazepine side effects, a 60-patient comparison against phenazepam with effects persisting a week after dosing, a study of IL-6 gene expression in depressed patients, and a placebo-controlled resting-state fMRI study in 52 healthy participants. All Russian, published in Russian-language journals, and none independently replicated in the West.
Animal / Preclinical
None for the modified form. The parent has a substantial rodent literature covering anxiolysis, diazepam potentiation under chronic mild stress, BDNF regulation, cytokine normalisation under social stress, enkephalinase inhibition, route-dependent receptor binding, and a long-duration study showing sustained anxiolysis over four weeks without weight change.
Mechanistic Rationale
Moderate for the parent, speculative for the variant. GABA-A allosteric modulation is supported by both radioligand and electrophysiological evidence, and the enkephalinase and BDNF mechanisms have primary support. The half-life-extension rationale for terminal capping is sound chemistry, but the assumption that it preserves pharmacology is contradicted by the one study that tested an acetylated sibling peptide.
Research Gaps & Open Questions
What the current literature has not yet settled about N-Acetyl Selank Amidate:
- 01Any publication whatsoever on the modified molecule. Systematic searches of PubMed across five phrase variants and of Europe PMC including preprints return zero records; the phrases do not exist in the biomedical index. This is a complete absence rather than a thin literature.
- 02Human pharmacokinetic comparison against standard Selank. The extended-half-life claim is the entire commercial rationale for this variant and has never been measured in any species.
- 03Whether terminal capping preserves the parent's pharmacology. The one relevant experiment — N-acetylation of the sibling peptide Semax — found altered metal coordination, altered redox behaviour and loss of a protective effect, with the free amino terminus identified as crucial. Nothing equivalent has been done for Selank.
- 04Comparative efficacy against standard Selank for anxiolytic outcomes. No head-to-head of any kind exists, and no new comparative human data has appeared in periodic sweeps through 2026.
- 05Product-quality verification. No independent analysis has confirmed the identity, purity or correct terminal modification of any commercial preparation — and unlike the parent, which has been found in seized-preparation forensic work, the variant has no reference characterisation in the literature to check against.
- 06Toxicology of any kind. No study has examined the modified peptide in any model, and the FDA's concern about aggregation and peptide-related impurities in the parent has never been evaluated for the analogue.
- 07Independent Western replication of the parent's clinical findings. Selank's human evidence is entirely Russian and published in Russian-language journals; no Western trial has reproduced the anxiolytic or benzodiazepine-sparing results.
Forms & Administration
Intranasal spray or solution is the route described in essentially all user protocols, inherited from the parent's design rationale; subcutaneous injection is sometimes described. Typical reported doses are 200-600 mcg intranasally, one to three times daily, often in 2-4 week cycles. None of these parameters derives from a study of this molecule. All injectable peptides should only be administered under the guidance of a qualified healthcare provider, and this one has no clinical data to guide anyone.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Forum-described protocols typically use 200-600 mcg per dose intranasally, with some citing 100-400 mcg on the assumption that a stabilised peptide delivers comparable exposure at a lower dose. That assumption has no published support. No approved clinical protocol exists for this variant, and no human pharmacokinetic study has ever compared it to standard Selank.
Frequency
Intranasal dosing is typically described once or twice daily, sometimes three times during high-stress periods. The theoretical rationale for terminal capping — longer half-life — would argue for less frequent dosing than standard Selank, but no comparative human PK data exists to confirm the premise, let alone to set an interval.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Forum users typically describe 2-4 week cycles with breaks. For context from the parent peptide, a long-duration rodent study of daily tuftsin-analogue dosing over four weeks reported anxiolysis from day two sustained throughout with no body-weight change, and the human trial of Selank against phenazepam reported effects persisting for a week after the last dose. Neither finding transfers automatically to the modified molecule.
Protocol Notes
Intranasal delivery is the route described in nearly all protocols, inherited from Selank's design rationale, and the terminal modifications are intended to reduce nasal and systemic peptidase cleavage so more intact peptide reaches CNS targets. Administration follows the parent: drops or spray into each nostril, head slightly tilted back, distributed across the nasal mucosa, with nasal irritation the most commonly reported effect. There is a specific reason to be cautious about assuming route-independence here. A comparative mouse study found that Selank given intraperitoneally raised frontal cortex GABA receptor binding by about 38% with no NMDA change, while the same peptide given intranasally raised NMDA-site binding by about 23% with no GABA effect. If route alone reshapes which receptor systems respond, then a molecule that has been structurally modified to change its disposition cannot be assumed to reproduce the parent's pharmacology at any dose — and nobody has checked. Sourcing remains the central practical issue and it has a documented dimension. Forensic analysis of seized pharmaceutical preparations has found Selank and Semax circulating as lyophilised powder and nasal sprays, with the authors noting these peptides 'have not completed any clinical trials' while being freely sold online. For the acetylated amidated variant specifically, there is no way for a buyer to confirm that the terminal modifications are present and correct — the stability advantage that justifies the premium is unverifiable by the purchaser, and the molecule has no reference standard in the literature against which anyone could check. The FDA's stated concern about the parent — potential immunogenicity from aggregation and peptide-related impurities — applies at least as strongly to a modified analogue made outside pharmaceutical manufacturing controls, since aggregation behaviour is specific to the exact molecule and formulation.
N-Acetyl Selank Amidate is not approved as a medicine in any jurisdiction, including Russia where the parent peptide is registered. It is not FDA-approved, is not a lawful dietary supplement ingredient, and has no compounding pathway — the parent's compounding nomination was withdrawn from FDA consideration. It is sold through research-chemical channels not authorised for human use.
Timeline of Effects
Onset
Anecdotally described as similar to standard Selank — roughly 15-45 minutes to subjective reduction in anxiety or improved stress tolerance. The human fMRI study of the parent detected connectivity changes within 5 to 20 minutes of injection, which is at least consistent with a rapid central effect for the parent molecule. No controlled study has characterised onset for this variant, and reports of faster or stronger onset than Selank are not independently verified.
Peak Effect
Anecdotally 1-3 hours post-dose, with users reporting longer duration than standard Selank consistent with the intended half-life extension — again unconfirmed by any published pharmacokinetic comparison. Cumulative benefit over days to weeks is reported and matches the parent literature, where a human trial found anxiolytic effects persisting for a week after the final dose.
After Discontinuation
Acute effects fade within hours. No withdrawal syndrome or rebound anxiety has been described for the parent or the variant, which is one of the more defensible claims made for this peptide class and a genuine contrast with benzodiazepines. Longer-term changes attributable to accumulated BDNF-mediated signalling may persist for days to weeks, inferred from the parent's rodent literature.
Monitoring & Measurement
Bloodwork & Labs
- •No biomarker exists for this peptide or its activity — there is no clinical assay for Selank or its analogues
- •Thyroid function and ferritin, where anxiety or fatigue could have a treatable medical driver that a peptide will not address
Functional & Performance Tests
- •GAD-7 (Generalized Anxiety Disorder 7-item scale) — brief, validated, and the most practical self-administered measure
- •State-Trait Anxiety Inventory, or the Hamilton and Zung scales used in the Selank trials themselves, for closer comparability to the published results
- •Clinical Global Impression scale, also used in the Selank trials
- •Objective cognitive testing where the claim being evaluated is focus or mental clarity rather than anxiety, since subjective nootropic effects are notoriously placebo-sensitive
When to Test
Establish a baseline over at least two weeks before starting, then reassess at the end of a defined period rather than judging day to day. The Selank trials assessed outcomes over courses of weeks, and the comparison against phenazepam found effects persisting for a week after the final dose — so a post-course measurement taken immediately may not capture the full picture.
Interpretation & Notes
This section exists because anxiety is one of the few peptide use cases with genuinely good, free, validated measurement tools. The GAD-7 takes two minutes and has established severity cut-offs; using it before and after a defined trial period converts an impression into something comparable. The reason that matters more here than elsewhere is the evidence vacuum. With no pharmacokinetic data, no efficacy data and no way to verify what is in the vial, a structured self-assessment against a baseline is the only information anyone using this compound will actually generate. It is also the measurement most likely to reveal that nothing is happening. The honest caveat is that an uncontrolled self-assessment cannot distinguish drug effect from placebo, regression to the mean, or the natural waxing and waning of anxiety — and anxiolytic self-report is precisely where expectancy effects are largest. None of this is a substitute for evaluation by a clinician, particularly since diagnosed anxiety disorders have treatments with evidence this compound does not approach.
Common Questions
How does this differ from regular Selank?
Chemically, the N-terminus is acetylated and the C-terminus amidated, which blocks the exopeptidases that cleave peptides from each end and should extend half-life. Clinically, nobody knows, because the modified molecule has never been studied. The core anxiolytic and nootropic mechanisms are assumed to carry over; that assumption has not been tested.
Is there really no research on it at all?
None. A systematic PubMed search across five phrase variants returns zero results — PubMed reports that the phrases do not appear in its index. Europe PMC returns zero including preprints, and ClinicalTrials.gov has no record. This is not a case of thin or low-quality evidence; it is a complete absence, and it is unusual to be able to state that so definitively.
Is it actually clinically superior to standard Selank?
Not demonstrated, and there is now a reason for active scepticism rather than mere agnosticism. The one time researchers acetylated the N-terminus of a closely related peptide — Semax, from the same Russian family — the modification changed its copper coordination and redox behaviour and abolished its protection against copper-induced toxicity in neuroblastoma cells, with the authors concluding the free amino terminus was crucial to that protective effect. Terminal capping is not a neutral operation on a peptide's biology. It may extend half-life and alter activity at the same time.
Is N-Acetyl Selank Amidate approved anywhere?
No. The parent Selank is registered as an anxiolytic in the Russian Federation — one of fourteen peptide drugs listed in a 2022 peer-reviewed survey of the Russian register. The acetylated amidated variant has no registration identified in any public regulatory database in any jurisdiction. In the United States, the parent compound is relevant in one specific way: 'Selank acetate (TP-7)' appears on the FDA's list of bulk drug substances that were nominated for compounding and then withdrawn from consideration, with the agency citing potential immunogenicity from aggregation and peptide-related impurities and a lack of information about safety issues in humans.
What does the parent peptide actually do?
Selank is a synthetic analogue of tuftsin — the tetrapeptide with Pro-Gly-Pro attached — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Radioligand work indicates it is a positive allosteric modulator of GABA binding that blocks diazepam's modulation, and patch-clamp recording found it increased the amplitude and frequency of spontaneous inhibitory postsynaptic currents in hippocampal CA1 neurons. It inhibits enkephalin-degrading enzymes in human serum, raises BDNF in hippocampus and prefrontal cortex in rats, and normalises IL-1β, IL-6, TNF-α and TGF-β1 under social stress. Note that interferon-gamma, often listed among its immune effects including by an earlier version of this page, does not appear to have been measured in any published Selank study.
Can I just use regular Selank instead?
That is the more evidence-based choice if someone is going to use either, since the parent has actual human trials behind it and the variant has none. It is not a regulatory upgrade: Selank is not approved outside Russia, is not a lawful dietary supplement ingredient in the US, and its FDA compounding nomination was withdrawn. But between a compound with a 62-patient controlled trial and a compound with zero publications, the asymmetry is not subtle.
Is it detectable in a drug test, and is it banned in sport?
Neither Selank nor this variant is named on the WADA 2027 Prohibited List — a text search of the published list returns no occurrence. But because neither is approved for human therapeutic use by any governmental health authority outside Russia, the S0 catch-all applies: unapproved pharmacological substances are prohibited at all times. Athletes should treat it as banned. Forensic analytical work has already found Selank and Semax in seized pharmaceutical preparations, so detection methods exist.
Who N-Acetyl Selank Amidate Is NOT For
- •Pregnancy — no safety data for this variant; reproductive toxicology not studied for either the variant or the parent.
- •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
- •Known hypersensitivity to Selank, to this variant, or to components of the intranasal vehicle.
- •Severe nasal mucosal disease, chronic rhinitis, or recent nasal surgery — intranasal delivery may be poorly tolerated and absorption would be unpredictable.
- •Concurrent benzodiazepines or other strong GABAergic sedatives without clinician oversight — the parent potentiates diazepam in rodent models and modulates GABA binding allosterically, and the human data showing it alters benzodiazepine side-effect profiles confirms a real pharmacodynamic interaction.
- •Pediatric use — no data in pediatric populations in any formulation.
- •Anyone using it in place of evaluation and treatment for a diagnosed anxiety disorder, which has effective evidence-based options that this compound does not have.
Drug & Supplement Interactions
No clinical interaction data exists for N-Acetyl Selank Amidate, and interactions must be inferred from the parent — with the caveat that a terminally modified peptide may not reproduce the parent's pharmacology. The benzodiazepine interaction is the best characterised and is not merely theoretical. Selank is a positive allosteric modulator of GABA binding that blocks diazepam's modulation at the receptor level, potentiates diazepam's anxiolytic effect in rats under chronic mild stress, and — in a 70-patient randomised human trial — reduced the side effects of phenazepam including attention and memory impairment, asthenia, sedation and sexual disturbance, both during treatment and after tranquilliser withdrawal. That is a genuine pharmacodynamic interaction documented in humans, and it cuts in a direction people may not anticipate: the parent appears to attenuate benzodiazepine side effects rather than simply adding to sedation. Whether the modified variant does the same is unknown. Interactions with serotonergic agents — SSRIs, SNRIs, MAOIs, triptans — are unstudied and unclear. Interactions with other nootropic peptides commonly stacked in forum protocols, including Semax and Cerebrolysin, have no data at all. The modifications are not thought to introduce new interaction mechanisms, since the parent's mechanistic profile is intended to be preserved and only half-life altered. But if half-life genuinely is extended, the window during which interactions could occur is correspondingly longer — and if, as the acetylated Semax work suggests, capping alters biology as well as durability, then the parent's interaction profile may not transfer cleanly. Anyone on regular psychiatric medication should disclose use to their prescriber. Because the product is not pharmaceutically regulated, interaction risk also includes unidentified impurities or off-target peptides from low-quality suppliers.
Safety Profile
Common Side Effects
Cautions
- • Not approved as a medicine anywhere, including Russia where the parent is registered
- • Zero published data specific to the modified form — no toxicology, no pharmacokinetics, no efficacy
- • Terminal acetylation changed the biology of a sibling peptide in the one study that looked
- • May interact with GABAergic medications, extrapolating from the parent's documented diazepam potentiation
- • Sold through research-chemical channels where identity and purity are unverified
What We Don't Know
Everything specific to this molecule. There is no published toxicology, no pharmacokinetic comparison against the parent, no efficacy study, no analytical characterisation, and no human exposure data of any kind. The safety case rests entirely on extrapolation from Selank — which itself has limited long-term human safety data, and whose FDA compounding nomination was withdrawn over concerns about immunogenicity from aggregation and peptide-related impurities. Those concerns are if anything more relevant to a modified analogue produced outside pharmaceutical manufacturing controls, since aggregation behaviour depends on the exact molecule and its formulation. A rare toxicology datapoint exists for the parent — Selank was tested alongside Semax on mouse embryonic stem cell proliferation, survival and neuronal differentiation — but nothing equivalent exists for the variant.
Legal Status
United States
Not FDA-approved for any indication. Not a controlled substance, not a recognised dietary supplement ingredient, and not a permitted cosmetic ingredient. No compounding pathway exists: the parent compound, listed as 'Selank acetate (TP-7)', appears among the bulk drug substances nominated for compounding and then withdrawn from FDA consideration, with the agency citing potential immunogenicity from aggregation and peptide-related impurities and a lack of information about human safety. The acetylated amidated variant has never been nominated. Sold through research-chemical suppliers whose labelling specifies non-human research use.
International
No registration identified in any public regulatory database, in any jurisdiction — stated as a negative search result rather than a positive finding, since the Russian and EAEU registers could not be queried directly. The parent Selank is registered as an anxiolytic in the Russian Federation, supported by a 2022 peer-reviewed survey listing it among fourteen peptide drugs on the Russian register; this page makes no claim about wider CIS registration, for which no source was found. Not approved in the EU, UK, Canada, Australia or Japan.
Sports & Competition
Neither this variant nor the parent Selank is named anywhere on the WADA Prohibited List — text extraction of both the 2026 and 2027 lists returns zero occurrences of selank, semax or tuftsin. S0 nonetheless applies: any pharmacological substance not addressed by a later section of the List and with no current approval by a governmental regulatory health authority for human therapeutic use is prohibited at all times, and this variant is approved nowhere. Athletes should assume it is prohibited. Detection is not hypothetical — forensic analytical work has already identified Selank and Semax in seized preparations, so methods exist.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
N-Acetyl Selank Amidate is an FDA-approved or clinically approved form of Selank.
Reality
It is not approved anywhere. The parent Selank is registered in the Russian Federation; this variant has no registration identified in any public regulatory database in any jurisdiction. In the US there is not even a compounding route — the parent was nominated as a bulk drug substance for compounding and then withdrawn from FDA consideration over potential immunogenicity from aggregation and peptide-related impurities.
Myth
The acetyl and amide modifications make it clinically superior to standard Selank.
Reality
No study has tested this in any species. Worse for the claim, the one time researchers acetylated the N-terminus of a closely related peptide — Semax — the modification changed its copper coordination chemistry and redox behaviour and abolished its protection against copper-induced toxicity in neuroblastoma cells, with the authors identifying the free amino terminus as crucial to that protection. Terminal capping is a real intervention in a peptide's biology, not a neutral preservative.
Myth
Because it is stabilised, it is safer than standard Selank.
Reality
Stability is not safety. A longer-lived peptide extends undesired effects along with desired ones, and the FDA's stated concern about the parent — aggregation and peptide-related impurities driving immunogenicity — applies at least as strongly to a modified analogue manufactured outside pharmaceutical controls, since aggregation behaviour depends on the specific molecule and formulation.
Myth
There is research supporting it; it just hasn't reached mainstream journals.
Reality
There is no research. PubMed returns zero results across five phrase variants and reports that the phrases do not appear in its index at all; Europe PMC returns zero including preprints; ClinicalTrials.gov has no record. This is not a question of obscure or non-English publication — Selank's own Russian-language trials are indexed in PubMed and cited on this page. The variant simply has not been studied.
Myth
Research-chemical sources are equivalent in quality to pharmaceutical Selank.
Reality
Pharmaceutical-grade Selank is manufactured under regulated conditions with identity and purity verification. Research-chemical product carries no such guarantee, and forensic analysis of seized preparations has found these peptides circulating as unregulated powders and nasal sprays. For this variant specifically there is an additional problem: with no published characterisation of the molecule, there is no reference standard a buyer or a laboratory could check a sample against.
Myth
Selank itself is unproven, so the variant is no worse off.
Reality
The parent has considerably more behind it than this page once suggested — a 62-patient comparator-controlled trial against medazepam, a 70-patient randomised trial showing reduced benzodiazepine side effects, a 60-patient comparison against phenazepam, radioligand evidence of GABA allosteric modulation, patch-clamp confirmation in hippocampal neurons, and a placebo-controlled fMRI study in 52 healthy participants. The gap between the parent and the variant is not small; it is the difference between a limited but real evidence base and none.
Published Research
21 studiesSelank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank
The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress
Functional Connectomic Approach to Studying Selank and Semax Effects.
Panikratova et al. (Dokl Biol Sci 2020) — the only modern human mechanistic imaging data on Selank, and the most methodologically contemporary study in this file. Resting-state fMRI in 52 healthy participants comparing Selank, Semax and placebo, scanned before injection and at 5 and 20 minutes after, found altered connectivity between right amygdala and right temporal cortex. Places a Russian-origin peptide into a mainstream neuroimaging paradigm.
The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.
Vyunova et al. (Protein Pept Lett 2018) — the best direct evidence for the GABAergic mechanism this page's parent peptide claims rest on, from the Institute of Molecular Genetics that created Selank. Radioligand assay identifies Selank as a positive allosteric modulator of GABA binding that blocks diazepam and olanzapine modulation, at sites apparently distinct from but possibly overlapping the benzodiazepine site.
[COMPARISON OF PHARMACOLOGICAL EFFECTS OF HEPTAPEPTIDE SELANK AFTER INTRANASAL AND INTRAPERITONEAL ADMINISTRATION TO BALB/c AND C57BL/6 MICE.]
Vasil'eva et al. (Eksp Klin Farmakol 2016) — strategically important for anyone assuming that changing a peptide's disposition leaves its pharmacology intact. Intraperitoneal Selank raised GABA receptor binding sites in frontal cortex by about 38% with no NMDA change, while intranasal Selank raised MK-801 (NMDA) site binding by about 23% with no GABA effect. The same molecule, different route, different receptor profile.
Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells
Effect of Selank on Spontaneous Synaptic Activity of Rat Hippocampal CA1 Neurons.
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells.
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.
Magrì et al. (J Inorg Biochem 2016) — the single most relevant study to this page, despite being about a different peptide. It is the only instance of anyone acetylating the N-terminus of a peptide in this family and testing what changed. Acetylation shifted the copper complex from a CuN4 to a distorted CuN3O chromophore and made it redox-reactive, and critically: 'Semax acetylation did not protect from Cu(II) induced toxicity on a SH-SY5Y neuroblastoma cell line, thus demonstrating the crucial role played by the free NH2 terminus in the cell protection.' Direct evidence that terminal capping alters biology rather than merely extending half-life.
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
[Optimization of the treatment of anxiety disorders with selank]
Medvedev et al. (Zh Nevrol Psikhiatr 2015) — 70 patients randomised to Selank plus phenazepam versus phenazepam alone. The Selank add-on reduced benzodiazepine side effects — attention and memory impairment, asthenia, sedation and sexual disturbance — both during treatment and after tranquilliser withdrawal. The most clinically interesting Selank result, and the direct evidence behind this page's benzodiazepine interaction discussion.
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
Stability of Semax acetyl to proteolysis in various biological media
[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]
Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia
Zozulya et al. (Zh Nevrol Psikhiatr 2008) — the principal human efficacy study for the parent peptide. Sixty-two patients with generalised anxiety disorder and neurasthenia, with Selank (n=30) compared against medazepam (n=32) using Hamilton, Zung and CGI scales plus serum enkephalin activity. Anxiolytic effects were comparable between the two, with Selank additionally showing antiasthenic and psychostimulant effects, and the study linked symptom severity to shortened leu-enkephalin half-life. Note this is a comparator-controlled trial, not the open-label study an earlier version of this page described.
Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
Quick Facts
- Class
- Nootropic Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Oct 2026
- Citations
- 21PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.